Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Mesothelioma
Stage/Subtype:  recurrent malignant mesothelioma
Trial Type:  Treatment
Results 1-22 of 22 for your search:
Start Over
Genetically Engineered Lymphocytes in Treating Patients with Metastatic Cancer or Cancer That Cannot Be Removed by Surgery Receiving Chemotherapy and Aldesleukin
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 66
Trial IDs: 12-C-0111, NCI-2013-01516, 1112-1139, 120111, P11928, RD-12-I-02, NCT01583686
Genetically Modified T Cells in Treating Patients with Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2727.00, NCI-2015-00329, 2727, NCT02408016
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients with Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Cisplatin and Pemetrexed
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PHI-76, NCI-2015-00127, 9837, NCT02535312
Pentostatin, Cyclophosphamide, and SS1(dsFv)-PE38 Immunotoxin in Treating Patients with Mesothelioma, Lung Cancer, or Pancreatic Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-C-0160, NCI-2013-01490, 110160, P10761, 8980, NCT01362790
Erlotinib Hydrochloride in Treating Patients with Malignant Peritoneal Mesothelioma
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-0032, NCI-2012-00332, NCT01592383
Pembrolizumab in Treating Patients with Malignant Mesothelioma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB14-1381, NCI-2015-00348, NCT02399371
Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 15743, NCI-2015-02207, 2012-003650-88, NCT02610140
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 3475-158, NCI-2015-02278, 163196, 2015-002067-41, NCT02628067
Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MCC-18094, NCI-2016-00002, NCT02611037
Nintedanib in Treating Patients with Malignant Pleural Mesothelioma That Is Recurrent or Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2015-010, NCI-2015-01412, 1506014121, NCT02568449
Vaccine Therapy and Celecoxib in Treating Patients with Lung Cancer, Esophageal Cancer, Thymic Cancers, Thoracic Sarcomas, or Malignant Pleural Mesotheliomas Undergoing Surgery
Status: Temporarily closed
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 11-C-0041, NCI-2013-01472, 110041, P09574, NCT01258868
Viral Therapy in Treating Patients with Primary, Metastatic, or Mesothelioma-Related Malignant Pleural Effusion
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-169, NCI-2013-00105, GL-ONC1-003/MSKCC, MSKCC-12169, NCT01766739
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EMR 100070-001, NCI-2013-02214, 2013-002834-19, NCT01772004
Heated Cisplatin following Surgery in Treating Younger Patients with Primary or Metastatic Pleural Malignancies
Status: Active
Phase: Phase I
Type: Treatment
Age: 3 to 21
Trial IDs: 2012-0657, NCI-2014-01101, NCI-2014-00510, NCT01998529
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CX-839-001, NCI-2014-01059, NCT02071862
Genetically Modified T Cells with or without Cyclophosphamide in Treating Patients with Recurrent Mesothelin-Expressing Cancers That Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCC 31213, NCI-2015-00392, 819826, NCT02159716
Mesothelin-Specific Genetically Engineered Lymphocytes with or without Cyclophosphamide in Treating Patients with Malignant Pleural Disease
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-007, NCI-2015-00789, NCT02414269
Pemetrexed and Cisplatin with Pleural IMRT in Treating Patients with Malignant Pleural Mesothelioma That Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 15-304, NCI-2015-02283, NCT02639767
Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 17631, NCI-2016-00280, NCT02639091
LMB-100 in Treating Patients with Malignant Mesothelioma That Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 16-C-0127, NCI-2016-01033, P152590, NCT02798536
Amatuximab in Treating Patients with Advanced Pancreatic, Mesothelioma, Ovarian, or Non-Small Cell Lung Cancer
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-C-0212, NCI-2013-01497, 009-006, 110212, P10769, NCT01413451
Proton Beam Radiation Therapy in Treating Patients with Recurrent Thoracic Cancer Who Have Received Prior Radiation Therapy
Status: Active
Phase: No phase specified
Type: Treatment
Age: 19 and older
Trial IDs: 9148, NCI-2014-01468, NCT02204761
Start Over